The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection

  • JACC Basic Transl Sci. 2021 Jan;6(1):1-8. doi: 10.1016/j.jacbts.2020.10.003.
Brandon J Beddingfield  1  2 ,  Naoki Iwanaga  3 ,  Prem P Chapagain  4  5 ,  Wenshu Zheng  6 ,  Chad J Roy  1  2 ,  Tony Y Hu  6 ,  Jay K Kolls  3 ,  Gregory J Bix  7  8  9  10  11
Affiliations
  • 1. Division of Microbiology, Tulane National Primate Research Center, Covington, Louisiana, USA.
  • 2. Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • 3. Departments of Pediatrics and Medicine, Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • 4. Department of Physics, Florida International University, Miami, Florida, USA.
  • 5. Biomolecular Sciences Institute, Florida International University, Miami, Florida, USA.
  • 6. Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • 7. Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • 8. Department of Neurosurgery, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • 9. Department of Neurology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • 10. Tulane Brain Institute, Tulane University, New Orleans, Louisiana, USA.
  • 11. Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
PMID: 33102950 DOI: 10.1016/j.jacbts.2020.10.003
Abstract

Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting angiotensin-converting enzyme-2 (ACE2) binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin-based mechanism and indicates that inhibiting the spike protein interaction with α5β1 Integrin (+/- ACE2) and the interaction between α5β1 Integrin and ACE2 using a novel molecule (ATN-161) represents a promising approach to treat coronavirus disease-19.

Keywords
ACE2; ACE2, angiotensin-converting enzyme 2; ATN-161; CO2, carbon dioxide; COVID-19; COVID-19, coronavirus disease-2019; DMEM, Dulbecco’s modified eagle media; ELISA, enzyme-linked immunosorbent assay; IC50, half-maximal inhibitory concentration; RBD, receptor binding domain; RGD, arginine-glycine-aspartate; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2; alpha5beta1 integrin; hACE2, human angiotensin-converting enzyme 2; host-cell entry; qPCR, quantitative polymerase chain reaction; receptor binding domain; therapeutic; viral spike protein.
Products